“In the near future, the strategic collaborations for manufacturing cancer generics will curtail the cost burden”, says RNCOS.
Noida, UP -- (SBWIRE) -- 12/17/2014 -- The cost burden created by high cost of branded oncology drugs is one of the major challenges faced by the global community, and the inability of a large proportion of the population to afford them is impacting the pharma market. So in order to deal with the predicament, market players in the cancer generic drugs segment have built their strategic decisions taking into account co-operation by governments. For this, they are now collaborating with other drug manufacturers to support large-scale production.
Pharma companies are now focusing on increasing their product portfolios in the generic segment. With major cancer drugs slated for patent expirations in the next few years and big pharmas such as Eli Lilly foraying into the generics industry, generics are going to be the next big thing in the field of oncology. Recently, ScinoPharm Taiwan and Coland have formed a strategic partnership in order to develop a series of generic oncological drugs for China. This partnership would ultimately strengthen R&D for the anti-cancerian drug market in China. Alongside this, India's Strides Acrolab and Eli Lily have also joined hands to distribute and manufacture generic cancer drugs so as to expand their presence in the developing markets. RNCOS in its latest research report titled "Global Cancer Generics Market Outlook 2018", has highlighted that the cancer generics market is anticipated to grow at a CAGR of around 12% during 2013-2018, surpassing US$ 20 Billion mark by then.
Holistically, our latest research report, elicits the global oncology market and global caner generics market. Cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to the major indications is also discussed in depth, emphasis on current and future incidence, regional analysis and the patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.
Moreover, the dossier also contains the analysis of the top notch global cancer generics manufacturers. On the holistic basis, the report is primarily inclined towards the in-depth study of global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labeling Cancer Generics as a field with substantial growth potential over the next few years.
For FREE SAMPLE of this report visit:
Check Related REPORTS on:
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.